Skip to main content
SpringerLink
Log in

Ridogrel

R 68070

  • Adis R&D Profile
  • Section 2: Inflammatory Bowel Disorders
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sica D, Gehr T, Ripley B, et al. Pk of ridogrel in male subjects. Clin Pharmacol Ther 1993 Feb; 53: 166

    Google Scholar 

  2. Van Dullemen HM, Tytgat SHA, Strijbos M, et al. Bioavailability of ridogrel administered orally and rectally to patients with ulcerative colitis. Gastroenterology 1995 Apr; 108 Suppl.: 933

    Article  Google Scholar 

  3. Yasuda T, Gold HK, Yaotia H, et al. Antithrombotic effects of ridogrel, a combined thromboxane A2 synthase inhibitor and prostaglandin endoperoxide-receptor antagonist, in a plateletmediated coronary artery occlusion preparation in the dog. Coron Artery Dis 1991 Dec; 2: 1103–10

    Google Scholar 

  4. Yao S-K, Ober JC, Ferguson JJ, et al. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation 1992 Dec; 86: 1993–9

    Article  PubMed  CAS  Google Scholar 

  5. Vandeplassche G, Hermans C, Somers Y, et al. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase. J Am Coll Cardiol 1993 Apr; 21: 1269–79

    Article  PubMed  CAS  Google Scholar 

  6. Van der Wieken LR, van den Brand M, et al. Ridogrel as adjunct to thrombolysis in acute myocardial infarction. Circulation 1992 Oct; 86 Suppl.: 47

    Article  Google Scholar 

  7. Tranchesi B, Pileggi F, Vercammen E, et al. Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. Eur Heart J 1994 May; 15: 660–4

    PubMed  CAS  Google Scholar 

  8. Skandalis N, Rotenberg A, Meuwissen S, et al. Ridogrel for the treatment of mild to moderate ulcerative colitis. Gastroenterology 1996 Apr; 110 Suppl.: 1016

    Google Scholar 

  9. Casellas F, Papo M, Guarner F, et al. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 1995 Mar; 7: 221–6

    PubMed  CAS  Google Scholar 

  10. Van Outryve M, Huble F, Van Eeghem P, et al. Comparison of ridogrel versus prednisolone, both administered rectally, for the treatment of active ulcerative colitis. Gastroenterology 1996 Apr; 110 Suppl.: 1035

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ridogrel. Drugs R&D 1, 270–272 (1999). https://doi.org/10.2165/00126839-199901030-00020

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901030-00020

Keywords

Search

Navigation